Breast Cancer
Bardia A et al. Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. ASCO 2022;Abstract 1071.
Chan A et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 2021;21(1):80-91.e7. Abstract
Cortes J et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217-26. Abstract
Finn RS et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. ASCO 2022;Abstract LBA1003.
Goetz M et al. MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). ESMO 2022;Abstract LAB15.
Harbeck N et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021;32(12):1571-81. Abstract
Hortobagyi GN et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022;386(10):942-50. Abstract
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-67. Abstract
von Minckwitz G et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380(7):617-28. Abstract
Gastrointestinal Cancers
Abou-Alfa GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1(8). Abstract
Cercek A et al. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. ASCO 2022;Abstract LBA5.
Cheng A-L. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract
Oh D-Y et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). ESMO 2022;Abstract 56P.
Rugo HS et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). ESMO 2022;Abstract LBA76.
Shitara K et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. Gastrointestinal Cancers Symposium 2023;Abstract LBA292.
Tie J et al. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. ASCO 2022;Abstract LBA1001.
Verset G et al. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: Data from the open-label, phase II KEYNOTE-224 trial. Clin Cancer Res 2022;28(12):2547-54. Abstract
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.
Yau T et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23(1):77-90. Abstract
Yoshino T et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). ASCO GI 2022;Abstract 119.
Genitourinary Cancers
Chi KN et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39(20):2294-303. Abstract
Choueiri TK et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). ESMO 2022;Abstract LBA8.
Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9). Abstract
Hoimes CJ et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol 2023;41(1):22-31. Abstract
Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract
James ND et al. Docetaxel for nonmetastatic prostate cancer: Long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectr 2022;6(4):pkac043. Abstract
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract
Chronic Lymphocytic Leukemia and Lymphomas
Alderuccio JP et al. Metabolic tumor volume predicts outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with loncastuximab tesirine in the Lotis-2 trial. ASH 2022;Abstract 2960.
Carlo-Stella C et al. Camidanlumab tesirine: Updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R CHL). EHA 2022;Abstract S201.
Dickinson M et al. Phase I study of YTB323, a chimeric antigen receptor (CAR)-T cell therapy manufactured using T-Charge™, in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA 2022;Abstract S212.
Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract
Maerevoet M et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. J Hematol Oncol 2021;14(1):111. Abstract
Qualls D et al. Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): Real world outcomes in a multicenter retrospective study. ASH 2022;Abstract 323.
Schuster M et al. Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL): A post-hoc analysis of the SADAL study. Clin Lymphoma Myeloma Leuk 2022;22(7):483-94. Abstract
Gynecologic Cancers
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
Maio M et al. Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial. ESMO 2022;Abstract 113P.
Makker V et al. A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (Study 111/KEYNOTE-146): Long-term efficacy and safety update. J Clin Oncol 2023;41(5):974-9. Abstract
Makker V et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. ASCO 2022;Abstract 5511.
Makker V et al. Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775. ESMO 2022;Abstract 525MO.
Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. J Clin Oncol 2023;[Online ahead of print]. Abstract
Oaknin A et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. ASCO 2022;Abstract 5509.
O’Malley DM et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study. J Clin Oncol 2022;40(7):752-61. Abstract
Yap TA et al. Avelumab plus talazoparib in patients with advanced solid tumors: The JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol. 2023 Jan 1;9(1):40-50. Abstract
Lung Cancer
Choudhury NJ et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. J Thorac Oncol 2022;[Online ahead of print]. Abstract
de Langen AJ et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial. Lancet 2023;[Online ahead of print]. Abstract
Goto K et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. ESMO 2022;Abstract LBA55.
Jänne PA et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 2022;387(2):120-31. Abstract
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract
Lu S et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): First interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2022;23(9):1167-79. Abstract
McCoach CE et al. Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001. J Thorac Oncol 2022;17(6):768-78. Abstract
O’Brien M et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23(10):1274-86. Abstract
Peters S et al. PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091. ESMO 2022;Abstract 930MO.
Ramalingam SS et al. Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP). ESMO 2022;Abstract 988P.
Shu CA et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. ASCO 2022;Abstract 9006.
Spigel DR et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301-11. Abstract